Use of tnf alpha inhibitor for treatment of erosive polyarthritis
AssigneeAbbVie Biotechnology Ltd.
InventorsRebecca S. Hoffman, Mark Weinberg
Life of this patent
Estimating the term…
Abstract
The invention describes methods of treating erosive polyarthritis comprising administering a TNFα antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNFα antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
Claims31
1-29. (canceled)
A method for treating erosive polyarthritis, comprising administering a human anti-TNFα antibody to a human subject having erosive polyarthritis associated with psoriatic arthritis, ankylosing spondylitis or juvenile rheumatoid arthritis, wherein a modified Total Sharp Score (mTSS) of the subject is maintained or decreased following said treating as compared to baseline prior to said treating, and wherein the human anti-TNFα antibody comprises (1) a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:
- 1 and (2) a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:
- 2.
A method for treating TNFα-related disorders capable of causing erosive polyarthritis, comprising administering a human anti-TNFα antibody to a human subject having erosive polyarthritis associated with psoriatic arthritis, ankylosing spondylitis or juvenile rheumatoid arthritis, such that radiographic progression in the human subject is inhibited, wherein the human anti-TNFα antibody comprises (1) a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:
- 1 and (2) a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:
- 2.
A method for treating structural damage associated with psoriatic arthritis, comprising administering adalimumab subcutaneously at a dose of 40 mg every other week to a human subject having structural damage associated with psoriatic arthritis, such that progression of structural damage in the human subject is inhibited or lessened.
Dependencies are inferred from the claim text.